Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lavone Bradfield

Internal Medicine Orlando, FL Medical Doctor

NPI 1871821447 CMS profile 2785592

21 Columbia St, Orlando, FL 32806

Open in the dashboard

General payments

$6,663

322 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lavone Bradfield of Orlando, FL is reported in the CMS Open Payments database as having received $6,663 across 322 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,942 69
2024 General $1,153 59
2023 General $1,472 77
2022 General $1,192 64
2021 General $462 26
2020 General $158 10
2019 General $284 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lavone Bradfield
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Lavone Bradfield were reported at $1,942. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Lavone Bradfield Internal Medicine median Middle half National median
2019 $284 $159 $48–$570 $163
2020 $158 $119 $33–$402 $114
2021 $462 $135 $37–$521 $132
2022 $1,192 $141 $42–$496 $149
2023 $1,472 $149 $45–$519 $160
2024 $1,153 $154 $47–$537 $164
2025 $1,942 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,642 60 payments
  2. Novo Nordisk Inc $1,041 52 payments
  3. AstraZeneca Pharmaceuticals LP $863 40 payments
  4. Lilly USA, LLC $559 33 payments
  5. Pfizer Inc. $300 17 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $266 15 payments
  7. Astellas Pharma US Inc $200 9 payments
  8. Daiichi Sankyo Inc. $191 10 payments
  9. Amgen Inc. $161 10 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $133 6 payments
  11. Other $1,306 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,561 318 payments
  2. Gift $59 1 payment
  3. Education $42 3 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,038 34 payments
  2. Ozempic $809 38 payments
  3. RYBELSUS $692 37 payments
  4. QULIPTA $588 18 payments
  5. FARXIGA $419 18 payments
  6. AIRSUPRA $347 12 payments
  7. MOUNJARO $326 18 payments
  8. BREZTRI $272 12 payments
  9. NURTEC ODT $270 15 payments
  10. VRAYLAR $268 12 payments
  11. Other $3,765 207 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 158 drugs

Part D claims

7,112

Median for Internal Medicine: 777

Drug cost

$610,857

Median for Internal Medicine: $73,373

Branded share of claims

19.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 72 $106,249
Mounjaro Tirzepatide Brand 44 $68,929
Otezla Apremilast Brand 13 $62,535
Jardiance Empagliflozin Brand 30 $46,745
Januvia Sitagliptin Phosphate Brand 42 $42,784
Ozempic Semaglutide Brand 33 $40,296
Rybelsus Semaglutide Brand 21 $39,851
Trulicity Dulaglutide Brand 19 $24,277
Xarelto Rivaroxaban Brand 14 $20,895
Repatha Sureclick Evolocumab Brand 22 $17,750

The 10 drugs with the highest cost, of 158 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$102,467

Of which drugs: $9,651

Medicare patients

352

Average age 76

Services billed

1,447

248 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 48%
Ischemic heart disease 39%
Diabetes 31%
Chronic kidney disease 30%
Depression 28%
Heart failure 26%
Atrial fibrillation 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 43 46 $3,655

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $128
$128 — —
QULIPTA
  • AbbVie, Inc. $90
$90 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $81
$81 — —
RYBELSUS
  • Novo Nordisk Inc $80
$80 21 —
Ozempic
  • Novo Nordisk Inc $80
$80 33 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

322 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record